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Background: Chronic chagasic cardiomyopathy is an inflammatory disease that occurs in approximately 30% of
patients infected by the protozoan Trypanosoma cruzi, and it has a profile of high morbidity and mortality. The worst
prognosis and the progression of this cardiomyopathy are associated with an exacerbated immune response and the
production of proinflammatory cytokines, which also occur in other cardiomyopathies. Some nutrients, including
omega-3 polyunsaturated fatty acids (PUFAs), promote the inhibition and/or stimulation of cytokine production. The
objective of this trial is to study the effects of omega-3 PUFA supplementation on the inflammatory response and lipid
profile in patients with chronic chagasic cardiomyopathy.
Methods/Design: This is a parallel, randomized, placebo-controlled, double-blind clinical trial with 40 patients that will
be conducted at a reference unit for Chagas disease patients, where the patients will be selected. The study will include
patients with chronic chagasic cardiomyopathy who are 18 years of age or older. The exclusion criteria are (a) ongoing
diarrheal disease, (b) inflammatory bowel disease, (c) diabetes or other endocrine disease, (d) use of fibrates, niacin, or
statins, (e) use of anti-inflammatory drugs, (f) pregnant and lactating women, (g) use of vitamin, mineral, or omega-3
supplementation during the previous 30 days, (h) hospital admission during the study, and (i) other associated
cardiomyopathies. The intervention will be treatment with omega-3 PUFAs at a dose of 3 g/day for 8 weeks,
compared to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory markers
(interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)α, interferon (IFN)γ, and transforming growth
factor (TGF)β). Secondary endpoints will be the fasting glucose, lipid, and anthropometric profiles. For statistical
analysis, we plan to run either a t test or Wilcoxon test (numerical variables) and Pearson’s χ2 or Fisher’s exact
test (categorical data), as appropriate.
Discussion: Evidence suggests that the anti-inflammatory action of omega-3 PUFAs may have beneficial effects on
chronic chagasic cardiomyopathy, as shown for other cardiomyopathies, due to improved control of the inflammatory
response. At the end of the study, we predict that patients will have lower inflammatory markers and an improved
metabolic and anthropometric profile.
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Chagas disease is endemic in Latin American countries,
where approximately 8 to 10 million people are infected
with Trypanosoma cruzi [1]. In Brazil, the number of in-
fected people is approximately 1.9 million, or 1% of the
Brazilian population [2].
The etiologic diagnosis of Chagas disease is performed
by detection of the parasite by parasitological methods (dir-
ect or indirect) and confirmed by two different serological
techniques indirect immunofluorescence and enzyme-
linked immunosorbent assay (ELISA) [3].
Chagas disease has two distinct clinical phases: acute
and chronic [3]. The chronic phase has three forms: in-
determinate, cardiac involvement, and/or digestive in-
volvement [3-5]. In most cases, acute disease is not
recognized at onset, and the individual remains asymp-
tomatic with no evidence of damage to any organ but
with reactive serology for Chagas disease and low para-
sitemia during the chronic phase [4]. After two or more
decades, 20% to 30% of patients progress to the cardiac
stage of the disease, when the majority of the deaths and
severe complications related to the disease occur [6-8].
Therefore, chronic chagasic cardiomyopathy (CCC) is an
important clinical form of Chagas disease due to its im-
pact on morbidity and its high mortality, worsening of
the quality of life, and limitation of the ability to work. It
is characterized by a myocarditis with multifocal mono-
nuclear inflammatory infiltrates, varying degrees of fi-
brosis, constant low-grade tissue parasitism, and low or
undetectable parasitemia [9] and it occurs earlier and
more severely in males [8,10]. Patients in the chronic
cardiac phase may manifest heart failure, ventricular and
atrial arrhythmias, atrioventricular blocks, thrombo-
embolism, stroke, and sudden death [2,7,11], which
together carry a high economic and mortality burden.
Once settled, CCC is progressive and tends worsen
due to overlap with inflammation, cell destruction, and
fibrosis. Some hypotheses have been proposed to explain
the nature of the cardiac inflammatory reaction, mainly
persistent heart immune response and reaction to the
parasite [12]. Cytokines are important mediators in the
maintenance of the inflammatory process, and they can
stimulate or inhibit the immune response [13]. Among
the several cytokines studied in T. cruzi infection, inter-
feron γ (IFNγ) has been associated with host resistance
to infection in both experimental models and humans
[14,15]. Transforming growth factor β (TGFβ) produc-
tion is increased in T. cruzi infection, and this increase
is most likely related to the fibrotic process observed in
CCC [16]. These results suggest that cytokines play
essential roles in controlling CCC morbidity [17-19].
Some nutrients are associated with the inhibition and/
or stimulation of cytokine production, including polyun-
saturated fatty acids (PUFAs). Omega-3 PUFAs (linolenicacid, eicosapentaenoic acid, and docosahexaenoic acid)
are found in vegetables (soy, canola, linseed) and cold-
water fish (mackerel, sardines, salmon, herring). PUFAs
are precursors to the biosynthesis of several important
metabolites, especially eicosanoids (prostaglandins, leu-
kotrienes, thromboxanes, lipoxins, and others), synthe-
sized from arachidonic acid [20]. Omega-6 PUFAs (such
as linoleic acid: 18:2n-6) and omega-3 PUFAs (such as
linolenic acid: 18:3n-3) are fundamental to the body and
have important roles in cell metabolism, including influen-
cing membrane fluidity, promoting the release of cyto-
kines, and acting as adhesion molecules on macrophages.
Thus, changes in their synthesis and metabolism may be
associated with endothelial and hemodynamic changes
that contribute to the increase in cardiovascular morbidity
and mortality [21].
The fatty acid composition of inflammatory cells can
be modified by increasing the intake of marine n-3 fatty
acids, which leads to a higher content of eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA). A
number of cell culture studies have reported that both
EPA and DHA decrease the activation of the transcription
factor nuclear factor κB (NFκB) in response to inflamma-
tory stimuli, such as lipopolysaccharide and inflammatory
cytokines [22]. Omega-3 PUFAs reduce arachidonic acid
content in cell membranes, resulting in the synthesis of ei-
cosanoids that have weaker inflammatory properties than
the eicosanoids derived from omega-6 PUFAs [23].
Omega-3 supplementation is safe and well tolerated in
infectious disease as demonstrated in HIV-infected pa-
tients treated with antiretroviral therapy [24,25], and on
host resistance to infection from Plasmodium berghei or
Plasmodium falciparum, the causative agents of malaria
[26], which like Chagas disease is a parasitic infection.
Several studies involving supplementation of the diet
with marine n-3 PUFAs in healthy human volunteers
have demonstrated decreased production of tumor ne-
crosis factor α (TNFα), interleukin 1β (IL-1β), IL-2, and
IL-6 [22,23,27]. Omega-3 PUFA supplementation for
8 weeks has been associated with an increase of periph-
eral mononuclear cells with high concentrations of EPA
and DHA, which have an immunomodulating effect [28].
In healthy adults, fish oil supplementation at 5 mL/day for
8 weeks reduced the production of IL-6 but did not
change the production of IL-10, TNFα, or IFNγ [29].
Long-chain omega-3 PUFA (EPA and DHA) plasma levels
are inversely associated with the risk of sudden death [30]
and may reduce the risk of ischemic heart disease [31].
EPA and DHA are also involved in the reduction of
plasma very-low-density lipoprotein cholesterol (VLDL-c)
and triglycerides [32].
A study conducted by the Italian group GISSI-HF at
326 cardiology sites and 31 internal medicine sites se-
lected 6,975 patients with heart failure diagnosis to
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(n = 3,494) or placebo (n = 3,481) [33]. The total mortal-
ity of the supplemented group was 27%, and that of the
placebo group was 29% (adjusted HR 0.91; 95.5% confi-
dence interval (CI) 0.833 to 0.998; P = 0.041). Hospital
admissions due to cardiovascular events were 57% in the
omega-3 PUFA group versus 59% in the placebo group
(adjusted HR 0.92; 99% CI 0.849 to 0.999; P = 0.009). The
advantages of n-3 PUFAs, which were reduced fatal events
and hospital admissions from cardiovascular causes, sug-
gest that they have an effect on the mechanisms leading to
progression of heart failure [33].
Supplementation with 1 g/day of omega-3 PUFAs in
capsules can decrease cardiovascular events by 10%
(death, myocardial infarction, stroke) in coronary arterial
disease patients [34]. Some studies that assessed the ef-
fect of omega-3 supplementation on the immune re-
sponse used EPA and/or DHA at 1 g to 9 g per day,
similar to the ingestion levels of Greenland Eskimos: 6
to 14 g/day, corresponding to 2.7% to 6.3% of their total
calorie intake. The highest doses can reduce arachidonic
acid in peripheral mononuclear cells [35].
Studies conducted in heart failure patients have not
shown adverse events after omega-3 supplementation
[33,36]. In contrast, studies in pregnant women and cancer
patients have reported gastrointestinal changes (diarrhea,
flatulence, gastroesophageal reflux, nausea), although no
differences between the treatment and placebo groups were
noted [37,38].
Few studies have evaluated the nutritional status of
Chagas patients. Three studies have evaluated patients
with the digestive form of the disease. In two of these
studies [39,40], there was a high prevalence of malnutri-
tion (>60%). The other study evaluated ten patients diag-
nosed as having megaesophagus, and only one had
malnutrition. The others were eutrophic or overweight
[41]. A study performed in São Paulo, Brazil, assessed
the nutritional state of 66 Chagas patients and found a
high prevalence of overweight and obesity (94%) and
large waist circumference (55%). The indeterminate form
of the disease was the most prevalent and constituted
71% of cases [42]. There are no reports in the literature
on the nutritional assessment of CCC patients.
Supplementation with omega-3 PUFAs may lead to in-
creased bodyweight in patients with heart cachexia, as
reported by a study that assessed 14 patients with severe
heart failure supplemented with 8 g/day omega-3 PUFAs
or placebo [43].
Although several studies have shown the beneficial ef-
fects of polyunsaturated fatty acids on inflammatory pro-
cesses, dyslipidemia, and cardiovascular diseases, there
are no reports about food intake and PUFA supplementa-
tion in CCC patients. Thus, the objective of this study is
to assess the effects of omega-3 PUFA supplementationon the lipid profile and the proinflammatory and anti-
inflammatory cytokine profiles in CCC patients.
Methods/Design
Study design
This is a parallel, double-blind, placebo-controlled clin-
ical trial with balanced randomization (1:1).
Settings
The proposed clinical trial will be held at a single site,
the Evandro Chagas Clinical Research Institute (IPEC),
which is one of the technical scientific units of the
Oswaldo Cruz Foundation (Fiocruz). IPEC is a 93-year-
old institution that is fully dedicated to clinical research
on infectious diseases, including Chagas disease. IPEC is
a major reference center for Chagas disease research,
care, and training.
Participants (inclusion and exclusion criteria)
Patients will be recruited from the cardiology ambula-
tory service at IPEC/Fiocruz, Rio de Janeiro, Brazil,
during the period determined for screening until the
minimum estimated sample size is reached. All pa-
tients had a previous epidemiologic history of Chagas
disease confirmed with at least two Chagas serology
tests (indirect immunofluorescence and ELISA), and
clinical evaluations, electrocardiographic and echocar-
diographic data obtained recently. Selected patients
will be older than 18 years, males and females with
CCC at stage B (no heart failure symptoms but with
segmental or global left ventricular systolic dysfunction
by echocardiogram), stage C (symptomatic heart fail-
ure), or stage D (end-stage heart failure), according to
the current Brazilian Chagas disease consensus [3].
The following exclusion criteria will be applied: diar-
rheal disease; inflammatory bowel syndrome; diagnosis
of diabetes or other endocrine pathologies; use of fibrates,
niacin, or statins; use of anti-inflammatory drugs; preg-
nant and lactating women; vitamin mineral or omega-3
supplementation during the previous 30 days; hospital ad-
mission during the study; and the presence of cardiomy-
opathies other than CCC.
Interventions: omega-3 versus corn oil placebo
Each participant will receive five omega-3 capsules per
day (1.8 g EPA and 1.2 g DHA) or placebo for 8 weeks
(Figure 1). The omega-3 and corn oil capsules will be
provided by Relthy Laboratórios Ltda. (Brazilian Health
Surveillance Agency (Agência Nacional de Vigilância
Sanitária (ANVISA)) registration: 6.2582.0022.001-1).
Endpoints
The primary endpoint of this study will be the cytokine
profile. IL-1, IL-2, IL-4, IL-6, IL-10, TNFα, IFNγ, and
Patient selection according to inclusion criteria in the 
cardiology ambulatory service at IPEC
Consent for study and Randomization
Omega-3 (1,8g EPA and 
1,2 g DHA)
Baseline assessment
- Inflammatory markers 
- Lipid profile
- Anthropometric  
- 24-hour recall and 3-day food 
Week 4
- Anthropometric
- 24-hour recall
Week 8
- Inflammatory markers 
- Lipid profile
- Anthropometric 
- 24-hour recall and 3-day food
Placebo (oil corn)
Figure 1 Study flow diagram for omega-3 supplementation in patients with chronic chagasic cardiomyopathy.
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specific sandwich enzyme-linked immunosorbent assays.
Capture and detection antibodies will be obtained from
eBioscience (San Diego, CA, USA). The tests will be
conducted according to the manufacturer’s instructions
and performed in triplicate.
The first secondary endpoint will be the lipid profile.
Total cholesterol, triglycerides, and high-density lipoproteincholesterol (HDL-c) will be measured with enzymatic col-
orimetric assays using Siemens reagents on a Siemens
Dimension RXL chemistry analyzer (Siemens Health-
care Diagnostics, Tarrytown, NY, USA). Low-density
lipoprotein cholesterol (LDL-c) and VLDL-c will be
calculated according to the Friedewald equation [44].
Another secondary endpoint of this trial will be an-
thropometric measures. The anthropometric assessment
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ence, tricipital skinfold thickness, and arm circumfer-
ence [45,46]. BMI will be determined using the standard
formula: BMI = weight/height2 [47].
Procedures, follow-up, and data collection
After patients are selected by cardiologists, they will be
seen by study nutritionists, who will explain the study
procedures to the patients and administer the free and
informed consent form. The patients who agree to par-
ticipate in the study will sign the consent form and
undergo the initial assessment.
The following data will be collected and evaluated in
the study: sociodemographic data (age, sex, ethnicity/
race, education, and domicile), clinical data (functional
class and vital signs), alcoholism, smoking, prescription
drugs, 3-day food record [48], 24-h recall [49], anthropo-
metric assessment (height, weight, BMI, waist circumfer-
ence, tricipital skinfold thickness, and arm circumference),
lipid profile (total cholesterol, triglycerides, HDL-c, LDL-
c, and VLDL-c), and cytokines (IL-1, IL-2, IL-4, IL-6,
IL-10, TNFα, IFNγ, and TGFβ). Clinical, nutritional,
and anthropometric assessments will take place imme-
diately before starting the intervention and after 4 and
8 weeks during the study; lipid profile and cytokines
will be evaluated before the intervention and at the end of
8 weeks. Each patient will be followed for 8 weeks.
Compliance with study treatment will be assessed by
the 3-day treatment recall and the number of omega-3/
placebo capsules returned. At every visit, the patients
will be asked about the number of doses of the pre-
scribed treatment that they did not take during the pre-
vious 3 days, and the ratio between the number of doses
taken and the number prescribed will be calculated. The
capsules will be dispensed at the beginning of the study
and after 4 weeks, and the returned capsules will be veri-
fied at weeks 4 and 8.
The dietary omega-3 PUFA intake will be followed-up
during the study (first visit and weeks 4 and 8) by ana-
lyzing the 24-h recall and 3-day food record, which are
considered indirect methods of analyzing the diet,
current dietary standards of a certain population, and
their development over time [50].
Patients may be excluded from the study in case of
complications during follow-up, such as significant
changes in intestinal transit, use of anti-inflammatory
drugs, and hospital admissions. Other complications
will be assessed by the study team. All endpoints will
be collected at time 0 and 8 weeks after omega-3/placebo
supplementation starts.
Safety monitoring
Patients will be followed up by a multidisciplinary team
at three time points: study start, week 4, and week 8.Possible complications will be assessed by the study car-
diologist and pharmacist. The safety assessment will
consist of monitoring adverse events, such as changes in
the digestive tract, physical exams, and laboratory tests.
Events, onset, and duration will be reported to the cardi-
ologist, who will determine if it is necessary to suspend
supplement use. Regular intake of omega-3 PUFAs is
not a risk to health. According to the US Food and Drug
Administration (FDA), the maximum intake of 3 g/day
EPA +DHA is considered safe [51].
Randomization and concealment
After the screening phase, patients will be randomly
assigned to 1 of 2 groups of 20 patients each: intervention
group or control group. Assignment to either group will
be performed by a computer-generated 1:1 randomization.
This assignment will occur within randomly ordered
blocks of size 4 or 6. This procedure will be conducted
using R project software with package ‘blockrand’ [52].
The allocation sequence will be concealed from the re-
searchers, who will enroll and assess participants in se-
quentially numbered, opaque, sealed, stapled envelopes.
To prevent subversion of the allocation sequence, the
name and date of birth of the participant will be written
on the envelope before the envelope is opened. The in-
formation in the envelope will be transferred onto the
allocation card inside the envelope. Corresponding enve-
lopes will be opened only after the enrolled participants
have completed all baseline assessments and at the time
of allocation to the intervention. These procedures will
be carried out by a professional without access to the
baseline evaluation results. The blister packaging and gel
capsules of omega-3 PUFAs and placebo will be identi-
cal. They will be identified by the lot number on the
package, which will be retained in the pharmacy, and
only the blisters will be provided to patients. The
pharmacist responsible for distribution and compliance
assessment will be the only person who can access this
information.
Blinding
The nutritionists and physician that will perform the ini-
tial evaluation before randomization, the monthly evalua-
tions and anthropometric profile, and the final evaluation
of the health care questionnaires after the end of the
patient follow-up will be blinded to the patients’
assignments.
Statistical methods
The EpiData [53] and Statistical Package for Social Sciences
[54] software will be used for data entry and analysis, re-
spectively. For categorical data, we will use Pearson’s χ2 or
Fisher’s exact test to verify the association between variables
in the two groups (omega-3 and placebo). Statistical
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numerical variables expressed as the mean and stand-
ard deviation (SD) or median and interquartile range.
The Kolmogorov-Smirnov test will be used to test the
normality of the sample distribution. The Student t
test will be used in cases with a normal distribution to
compare means between the two groups. The Wil-
coxon test will be used in cases with a non-normal
distribution. P values <0.05 will indicate a significant
association in all of the statistical tests used.
Minimum sample size estimation
The minimum estimated sample size is 40 patients ac-
cording to previous data, considering a prevalence of
60% of inadequate PUFA intake [55]. The following pa-
rameters were considered: baseline IFNγ = 3,986 ±
738 pg/mL, IFNγ after n-3 PUFA supplementation =
2,922 ± 1,275 pg/mL [56], power = 0.8, and α = 5%. We
used the R project software with package ‘Epicalc’
version 1.02 [57] to obtain this estimate.
Ethical issues
The study was approved by the Research Ethics committee
of the Evandro Chagas Clinical Research Institute (IPEC/
FIOCRUZ), registration number CAAE-0037.0.009.000-10
[58]. It is registered at ClinicalTrials.gov, number
NCT01863576. All study supplies and data collected
will be used exclusively in this study, and its results
will be made public, whether they are favorable or
not.
Discussion
Omega-3 PUFA intake is associated with beneficial
health effects. Omega-3 PUFAs are helpful in the preven-
tion and treatment of pathologies such as inflammatory
diseases, hypertension, hypertriglyceridemia, metabolic
syndrome, and heart diseases. An Italian study of heart
failure patients showed a reduction in mortality and
hospital admissions due to cardiovascular events, sug-
gesting beneficial effects of omega-3 PUFAs on the
progression of heart disease [33].
Omega-3 administration is effective at treating hypertri-
glyceridemia. According to clinical trials, supplementation
with 2 to 4 g of EPA/DHA per day may reduce triglyceride
levels by 25% to 30% [59] by decreasing the liver synthesis
of VLDL-c [34]. Omega-3 supplementation for chronic
chagasic cardiomyopathy may be similar to other cardio-
myopathies and promote reductions in triglyceride and
VLDL-c levels.
Omega-3 has beneficial effects against heart cachexia
after 18 weeks of supplementation [43]. Women with
polycystic ovarian syndrome and BMI between 25 and
40 kg/m2, however, exhibited no significant changes in
BMI after supplementation for 8 weeks [60]. The periodof treatment in this study may not be long enough to
observe significant anthropometric changes after omega-
3 administration with no other associated instruction or
intervention.
The action of omega-3 PUFAs is most likely related to
their anti-inflammatory effects, which are not yet com-
pletely understood; however, it is known that omega-3
PUFA supplementation reduces arachidonic acid content
in cell membranes, resulting in the synthesis of eicosa-
noids that are less inflammatory than the ones derived
from omega-6 PUFAs [23]. Omega-3 PUFAs can also de-
crease activation of NFκB in response to inflammatory
stimuli, such as lipopolysaccharide and inflammatory
cytokines [22]. A meta-analysis of the effects of fish oil
supplementation on the inflammatory markers of pa-
tients with chronic heart failure showed that circulating
TNFα, IL-1, and IL-6 (proinflammatory cytokines) de-
creased after a supplementation period of 3 to 12 months
with an EPA and DHA dose of 600 to 5,540 mg/day.
These data suggest that supplementation with higher
doses of omega-3 PUFAs or longer follow-up times are
associated with more substantially decreased cytokines
[61], which could benefit CCC patients.
A clinical trial evaluated 3-month omega-3 PUFA sup-
plementation in patients with heart failure. Patients were
divided into three groups: placebo, 1 g/day omega-3
PUFAs, and 4 g/day omega-3 PUFAs. Only the 4 g/day
group had an improvement in ventricular function with
an increase in the ejection fraction and endothelial func-
tion and a reduction in IL-6 [36]. We will use 3 g/day
omega-3 PUFAs in our study based on recent results
suggesting higher efficacy when compared to the usual
1 g dose, in addition to the fact that 3 g/day is considered
safe by the FDA [51]. According to a recent American
College of Cardiology and American Heart Association
(ACC/AHA) Heart Failure Guideline, omega-3 supple-
mentation is reasonable to use as adjunctive therapy in
heart failure patients (Class of Recommendation IIa, Level
of Evidence B ) [62].
The worse prognosis and progression of CCC are re-
lated to increased immune response with the production
of proinflammatory cytokines and the inhibition of anti-
inflammatory cytokines, which also occur in other car-
diomyopathies [63,64]. In Chagas disease, heart tissue is
an important target of T. cruzi infection, and substantial
amounts of proinflammatory cytokines, chemokines, and
enzymes, including inducible nitric oxide synthase and
metalloproteinases, are produced, resulting in inflamma-
tion and cardiac remodeling in response to parasite in-
fection [65]. Higher levels of IFNγ and TNFα are
associated with lower levels of IL-4 and IL-10, in both
cardiac and more severe forms of Chagas disease, and
high levels of IL-10 or moderate levels of IFNγ are asso-
ciated with the indeterminate form [15,66]. Omega-3
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IL-10 production, as shown in an experimental study in
Wistar rats supplemented with ethyl-eicosapentaenoic
acid and ethyl-γ-linolenic acid compared to a group
supplemented with palm oil [67]. Thus, omega-3 PUFA
supplementation in CCC patients may lead to in-
creased IL-4 and IL-10, reducing the inflammatory
effect on heart tissue.
Omega-3 PUFA supplementation, due to its anti-
inflammatory effects, is expected to decrease the serum
levels of proinflammatory cytokines, which are associ-
ated with the proliferation of parasites and the fibrotic
process characteristic of Chagas myocarditis. We thus
suppose that the benefits to CCC patients with regard to
the immunological profile could translate into a less
severe progression of cardiomyopathy, with subsequent
reduction in morbidity, in addition to secondary gains in
the lipid profile.
Trial status
This study is currently recruiting patients.
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